Beam terminates license pact with Bio Palette; Kobe University standby license activated

Beam Therapeutics Inc.

Mutual termination of License Agreement with Bio Palette effective March 2, 2026 due to Bio Palette's planned dissolution.
Standby License Agreement with Kobe University activated, granting Beam exclusive license to base editing patents previously covered.
No future payments due between Beam and Bio Palette under the Termination Agreement or License Agreement.
Beam retains rights to exploit base editing technology for human disease worldwide, minus microbiome field in Asia.

item 1.02

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Beam Therapeutics Inc. terminated License Agreement with Bio Palette Co., Ltd. (effective 2026-03-02).

Action: termination
Agreement: license
Counterparty: Bio Palette Co., Ltd.
Effective: 2026-03-02

Exact text from the filing

Beam Therapeutics Inc. (the “Company”) and Bio Palette Co., Ltd. (“Bio Palette”) mutually terminated the License Agreement by and between the Company and Bio Palette dated March 27, 2019 (the “License Agreement”)

View on SEC.gov

336 material agreements filed in the last 30 days. Browse all material agreements →

Beam Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-093914

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.